Marco Brughera
Director/Board Member at FENNEC PHARMACEUTICALS INC.
Net worth: - $ as of 29/04/2024
Marco Brughera active positions
| Companies | Position | Start | End |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. | Director/Board Member | 09/08/2016 | - |
| Independent Dir/Board Member | 09/08/2016 | - | |
Naicons Srl
 Naicons Srl Packaged SoftwareTechnology Services Naicons Srl develops a game-changing drug discovery platform. The private company is based in Milan, Italy. | Director/Board Member | - | - |
Leadiant Biosciences Ltd.
 Leadiant Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Leadiant Biosciences Ltd. researches, manufactures, and markets therapies for patients. The private company is based in London, UK, and has subsidiaries in Germany. The British company was founded in 1957. Antonio Gama da Silva has been the CEO of the company since 2016. | Director/Board Member | - | - |
Leadiant Biosciences SpA
 Leadiant Biosciences SpA Pharmaceuticals: MajorHealth Technology Part of Valline Srl, Leadiant Biosciences SpA develops and manufactures pharmaceutical therapies for patients with rare diseases. The company is based in Rome, Italy. The Italian company was founded in 1957. Marco Maria Brughera has been the CEO of the company since 2011. Leadiant Biosciences was acquired by CHIESI Farmaceutici SpA on October 20, 2020. | Director/Board Member | 31/12/2010 | - |
| Chief Executive Officer | 31/12/2010 | - | |
| Prassis - Istituto di Ricerche Sigma-Tau SpA | Chief Executive Officer | 31/12/2010 | - |
Exelead, Inc.
 Exelead, Inc. Pharmaceuticals: MajorHealth Technology Part of Merck KGaA, Exelead, Inc. is a biopharmaceutical contract development and manufacturing company. The company is based in Indianapolis, IN. John Rigg has been the CEO of the company since 2014. Exelead was acquired by Merck KGaA from Leadiant Biosciences SA on February 23, 2022 for $780 million. | Director/Board Member | - | - |
Career history of Marco Brughera
Former positions of Marco Brughera
| Companies | Position | Start | End |
|---|---|---|---|
| LEE'S PHARMACEUTICAL HOLDINGS LIMITED | Director/Board Member | 28/12/2014 | 28/12/2017 |
| GENTIUM S.P.A. (ADR) | Director/Board Member | 07/12/2011 | 31/12/2013 |
| Sigma-Tau Research Switzerland SA | President | 31/12/2010 | 30/09/2012 |
| ░░░░░░░░░ ░░░░░░░░░ ░░░░░░░░░░░░░ ░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░░ ░░░ ░░░░ ░░░░░░░░ ░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - |
| ░░░░░░░ ░░ ░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
| ░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - | |
| ░░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
| ░░░░░░░░░ | - | - | |
| ░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - | |
| ░░░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░░░ | ░░░░░░░░░░ | - | |
| ░░░░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - |
Training of Marco Brughera
| University of Milan | Doctorate Degree |
Statistics
International
| Italy | 11 |
| United States | 5 |
| United Kingdom | 3 |
Operational
| Director/Board Member | 10 |
| Chief Executive Officer | 5 |
| Corporate Officer/Principal | 3 |
Sectoral
| Health Technology | 13 |
| Consumer Services | 2 |
| Producer Manufacturing | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| SOLIGENIX, INC. | Health Technology |
| LEE'S PHARMACEUTICAL HOLDINGS LIMITED | Health Technology |
| FENNEC PHARMACEUTICALS INC. | Health Technology |
| Private companies | 15 |
|---|---|
Gentium Srl
 Gentium Srl Pharmaceuticals: MajorHealth Technology Gentium SRL manufactures and develops biopharmaceutical products. It offers discovery, research, development and manufacture of drugs for the treatment and prevention of a variety of vascular diseases and conditions related to cancer and cancer treatments. The company was founded by Laura Iris Ferro and is headquartered in Villa Guardia, Italy. | Health Technology |
Essetifin SpA
 Essetifin SpA Pharmaceuticals: MajorHealth Technology Essetifin SpA operates as a holding company. The company was founded in 1957 and is headquartered in Rome, Italy. | Health Technology |
| Sigma-Tau Research Switzerland SA | |
| Prassis - Istituto di Ricerche Sigma-Tau SpA | |
Tecnogen SpA
 Tecnogen SpA Electrical ProductsProducer Manufacturing Tecnogen SpA provides electric generators. It also offers lighting towers. The firm has a capacity of 35000 units for the global market and has branch offices in the United Kingdom, Germany, and Singapore. The company is headquartered in Piacenza, Italy. | Producer Manufacturing |
Leadiant Biosciences, Inc.
 Leadiant Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Leadiant Biosciences, Inc. operates as a research-based pharmaceutical company. It develops and commercializes medicines for rare diseases. The company was founded in 1989 by Claudio Cavazza and is headquartered in Gaithersburg, MD. | Health Technology |
Servier IP UK Ltd.
 Servier IP UK Ltd. Medical DistributorsDistribution Services Part of Baxter International, Inc., Servier IP UK Ltd. is a company that wholesales pharmaceutical products. Servier IP UK Ltd. is based in Slough, UK. Servier IP was acquired by Baxter International, Inc. from Essetifin SpA on July 23, 2015 for $1,255.92 million. | Distribution Services |
| Sigma Tau Rare Diseases SA | |
Nerviano Medical Sciences SRL
 Nerviano Medical Sciences SRL Pharmaceuticals: MajorHealth Technology Nerviano Medical Sciences SRL provides pharmaceutical services. The company is headquartered in Nerviano, Italy. | Health Technology |
Accelera Srl
 Accelera Srl BiotechnologyHealth Technology Accelera SRL operates as an drug discovery development research organization. It offers discovery, development, and bioanalysis and PK services. The company is headquartered in Nerviano, Italy. | Health Technology |
Leadiant Biosciences SpA
Leadiant Biosciences SpA Pharmaceuticals: MajorHealth Technology Part of Valline Srl, Leadiant Biosciences SpA develops and manufactures pharmaceutical therapies for patients with rare diseases. The company is based in Rome, Italy. The Italian company was founded in 1957. Marco Maria Brughera has been the CEO of the company since 2011. Leadiant Biosciences was acquired by CHIESI Farmaceutici SpA on October 20, 2020. | Health Technology |
Sigma-Tau Industrie Farmaceutiche Riunite SpA
 Sigma-Tau Industrie Farmaceutiche Riunite SpA Pharmaceuticals: MajorHealth Technology Sigma-Tau Industrie Farmaceutiche Riunite SpA engages in the provision of biopharmacological research and technology development services. It offers pharmaceutical products for therapeutic areas, such as cardiology and metabolism, gastroenterology, infectious diseases, urology, rheumatology, osteoporosis, neurology, psychiatry, and oncology. The company was founded by Emilio Cavazza and Claudio Cavazza in 1957 and is headquartered in Rome, Italy. | Health Technology |
Leadiant Biosciences Ltd.
Leadiant Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Leadiant Biosciences Ltd. researches, manufactures, and markets therapies for patients. The private company is based in London, UK, and has subsidiaries in Germany. The British company was founded in 1957. Antonio Gama da Silva has been the CEO of the company since 2016. | Health Technology |
Naicons Srl
Naicons Srl Packaged SoftwareTechnology Services Naicons Srl develops a game-changing drug discovery platform. The private company is based in Milan, Italy. | Technology Services |
Exelead, Inc.
Exelead, Inc. Pharmaceuticals: MajorHealth Technology Part of Merck KGaA, Exelead, Inc. is a biopharmaceutical contract development and manufacturing company. The company is based in Indianapolis, IN. John Rigg has been the CEO of the company since 2014. Exelead was acquired by Merck KGaA from Leadiant Biosciences SA on February 23, 2022 for $780 million. | Health Technology |
- Stock Market
- Insiders
- Marco Brughera
- Experience
